Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Academisch Ziekenhuis Maastricht operates as medical research centre. The company is headquartered in Maastricht, the Netherlands.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

A leader in therapeutic antibodies, ImClone Systems (also called "the company") is committed to advancing oncology care by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. Founded in 1984, ImClone has a rich culture of discovery and deep expertise in oncology. The company has utilized the many advances made in the fields of molecular biology, oncology, genomics, and antibody engineering to build a novel pipeline of product candidates designed to address specific genetic mechanisms involved in cancer growth and development. Beyond its blockbuster marketed product ERBITUX®, ImClone has several additional investigational monoclonal antibodies in various stages of clinical development. Following its acquisition by Eli Lilly and Company in 2008, ImClone Systems is accelerating its antibody pipeline development by leveraging Lilly's global capabilities. ImClone's pipeline has several molecules in mid- to late-stage clinical development targeting virtually all major solid tumor types. Additionally, ImClone plans to advance several additional targets from its research programs into clinical development over the coming years. ImClone's research and clinical development capabilities are augmented by its expertise in the scale-up and manufacturing of biologics. The company's state-of-the-art FDA-approved manufacturing facilities in Branchburg, New Jersey, provide it with one of the largest biologic manufacturing capacities in the world. ImClone's Branchburg campus also houses it clinical development and administration operations. The company's research headquarters are based in New York City and it has international operations in Europe.

AlphaVax develops a range of vaccine products for infectious diseases, biodefense, and cancer. It uses alphavaccine vector platform technology to generate a portfolio of vaccine candidates for infectious disease prevention and cancer immunotherapy. AlphaVax was founded by Jonathan F. Smith and is based in Durham, North Carolina.

Research Development Foundation is an American private company that operates as noncommercial research organizations.

Cancer Research Malaysia is a non-profit research organization finding ways to prevent, detect, diagnose, and cure cancer.

Oxxon Therapeutics Ltd. is a company headquartered in Oxford, UK. The firm operates as a biotechnology company. It was founded in 1998.

PCI Biotech AS, a subsidiary of PCI Biotech Holding ASA, is a company headquartered in Lysaker, Norway, that engages in research and development in biotechnology.\nThe company says this about itself: PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery). Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company's lead fimaChem programme consists of a clinical Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies

Mect Corp. manufactures cooling systems and self-developed dispensers. Its products include micro dispensers, micro dosing devices, adhesive dosing devices, gluing devices and micro pumps. The company was founded on August 12, 1981 and is headquartered in Osaka, Japan.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. mRNA programs include novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive), molecular therapies designed to trigger the body’s own production of therapeutic proteins (RNArt), and RNA encoded antibodies (RNAntibody). Its most advanced product candidate, CV9104, is being developed in Phase IIb for the treatment of prostate cancer.

Qinhuangdao Weiming Jianchangxing Medical and Health Technology Co., Ltd., established on 2021-08-19, Business scope includes cell therapy and gene detection technology,Technology research and development of gene therapy,Technology Promotion,technical consulting,technology transfer,Technical Services;stem cell technology,Development of immune cell technology;Biological reagent research and development and sales;Cell Preparation and Storage;health management(Except for medical treatment activities subject to approval);Health Advisory(Except for medical treatment activities subject to approval);Clinical Laboratory Services;medical instruments,Experimental Equipment Consumables,chemical reagent(Free of Hazardous Chemicals),Pharmaceutical raw materials(Excluding pre-licensed items)promotion of;Internet sales of daily necessities,cosmetic,Edible produce,Healthy food;Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval)**(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Riken Corp. engages in the manufacture and sale of engine and vehicular components. It operates through the Automotive and Machinery Parts, and Others segments. The Automotive and Machinery Parts segment deals with the company's core products such as piston rings, camshafts, seal rings for transmissions, high-grade cast iron products, and valve lifters. The Others segment includes plumbing equipment business, Electromagnetic Compatibility (EMC) business, and thermal engineering business, The company was founded by Masatoshi Okochi in November 1927 and is headquartered in Tokyo, Japan.

Henan Hualong Biotechnology Co., Ltd., established on 2012-05-07, Business scope includes biotechnology development,consult,Serve;Stem Cell Storage Services(Except where prohibited by the state).(All projects involving licensed operation shall be operated with a license)

Acen Med is a biomedical research and advanced cell engineering firm. Their products include stem cell preparations, 3D printed stem cell products, stem cell extracts, immune cell preparations, serum-free medium, cell bioreactors, and cell storage.